skip to main content

Amgen Educational Outreach Program: R&D Insights from Lab Bench to Patient Bedside

Monday, February 24, 2020
12:15pm to 5:15pm
Add to Cal

Hear from Amgen scientists about:

  • Identifying a possible therapeutic target and its role in disease
  • Case studies from bench to clinic
  • Leveraging technology to enable next-generation biopharmaceutical research


12:15-1:00 — Introduction to Biotechnology/Overview of Amgen's Drug Discovery and Development Process
1:00-2:00 — Discovery of AimovigTM(erenumab-aooe), the First FDA-Approved Antibody Therapeutic for Migraine
2:00-2:15 — BREAK
2:15-3:15 — Discovery of AMG 510, a first-in-human covalent inhibitor of KRASG12C for the treatment of solid tumors
3:15-4:15 — Leveraging Technology to Enable Next-Generation Biopharmaceutical Research
4:15-5:15 — Career Opportunities Session - Learn More About Opportunities at Amgen
For more information, please contact Prof. Gregory Fu / Julianne Just by phone at 626-395-2924 or by email at [email protected] or visit